CLN5 and cancer: Given BMPs markedly inhibit the cancer stem-like cells in other neoplasms, both from the central nervous system such as oligodendrogliomas [52] or from nonneural origin such as prostate [53] or breast tumors [54], the development of BMP-based treatments may provide new opportunities for therapeutic intervention of different cancer types besides GBM.